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Abstract 
Medication nonadherence among consumers with psychiatric disorders can significantly affect the health 
and wellbeing of the consumer and their family. Previous research has suggested that carers have an 
impact on consumer attitudes toward medication and adherence. Yet, how carer attitudes toward 
medication may be related to consumer attitudes and adherence has received little investigation. This 
exploratory study aimed to investigate the relationships between carer and consumer attitudes toward 
medication and consumer adherence behaviour. A cross-sectional survey assessing consumer and carer 
attitudes toward medication and consumer adherence was conducted amongst 42 consumer-carer 
dyads. Correlation analyses showed a positive association between consumer and carer attitudes toward 
medication and between consumer and carer attitudes with adherence. There was a general indication 
that the greater the difference between consumer and carer attitudes, the lower the level of adherence. 
Regression analyses revealed that while neither consumer nor carer attitudes were significant predictors 
of adherence, carer attitudes appeared to have a stronger role in adherence than consumer attitudes. 
These preliminary results highlight the importance of carer attitudes in relation to patient perceptions and 
behaviours toward medication, and thus the potential benefits of addressing both consumer and carer 
attitudes in any intervention for improving adherence. 
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1. Introduction 
Pharmacotherapy is generally recognised as an important component in the 
treatment and management of schizophrenia, bipolar, and depression (Barnes and British 
Assoc, 2011; Cleare et al., 2015; Goodwin et al., 2016). Yet, nonadherence to medication 
has been reported as greater than 50% amongst mental health consumers for these 
disorders (Castle et al., 2012; Ibrahim et al., 2015; Levin et al., 2016; Shafrin et al., 
2016). Non-adherence has been defined as clinically significant deviation from the 
dosage prescribed and exists on a continuum from completely adherent, through levels of 
partial adherence, to not taking medication at all (Aslani and du Pasquier, 2002). 
Complete or even partial nonadherence may significantly affect the health and wellbeing 
of the consumer and their family and has considerable financial implications for the 
health system (Ascher-Svanum et al., 2006; Gilmer et al., 2004; Hudson et al., 2004; 
Lacro et al., 2002). Non-adherence in schizophrenia often results in illness exacerbation, 
relapse, and increased re-hospitalisation (Coombs et al., 2003; Day et al., 2005; Dolder et 
al., 2003; Kikkert et al., 2008; Lacro et al., 2002; Marland and Cash, 2001; Rettenbacher 
et al., 2004). 
A number of factors have been identified as contributing to medication 
nonadherence such as psychopathology, cognitive impairment, insight, number and 
severity of side effects, complexity of dosing pattern, clinician skill, and social support 
(Fleishchacker et al., 2003).  This paper focuses on how consumer and carer attitudes 
impact adherence. 
Previous research has established the importance of subjective attitudes and 
beliefs of consumers towards their illness and medication in promoting medication 
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adherence. Consumers who hold negative beliefs and attitudes towards medication, are 
less likely to engage in adherence behaviour, while consumers with positive beliefs tend 
to have higher medication adherence (Lacro et al., 2002; Loffler et al., 2003; 
Rettenbacher et al., 2004).  Rettenbacher et al (2004) found a positive correlation 
between medication adherence and the consumer’s subjective belief as to whether they 
felt the drug had a positive effect on their illness. It was also found that adherent 
consumers more often reported the positive effect of medication on their illness and 
indicated this to be a reason for taking medication in comparison to nonadherent 
consumers.  Similarly, a study among psychiatric consumers in Norway reported that 
nonadherent consumers felt medication to be less necessary and were more concerned 
about it than adherent consumers (Jonsdottir et al., 2009). 
Less research has examined how the attitudes of individuals such as family 
members who care for the consumer may shape consumer adherence. Consumer 
subjective attitudes and beliefs towards medication are developed within an environment 
in which a consumer is likely to draw on multiple sources of information (Byrne et al., 
2008). These sources of information include those significant people around them. In a 
study of 122 consumers with bipolar disorder more positive medication attitudes were 
predicted by higher levels of social support and stronger beliefs that their health is 
influenced by important people in their social environment (Chang et al., 2015).It has 
been suggested that negative attitudes towards treatment in patients’ social environments 
can have adverse effects on adherence and that it is important to reinforce positive 
attitudes toward treatment for both patients and relatives (Fleischhacker et al., 2003). 
Other research has shown an association between carer and consumer attitudes about 
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their illness or treatment and found that carer attitudes can impact consumer outcomes. A 
Latin American study of consumers with schizophrenia and their carers investigated the 
association between causal belief of schizophrenia with attitudes toward medicine and 
symptoms (Caqueo-Urizar et al., 2015). Consumer and carer causal beliefs shared small 
to moderate correlations (e.g., biological causal belief r=.45). Stronger consumer and 
carer “magical-religious causal belief” were significantly associated with more negative 
attitudes toward medicine (r=-0.18 and r=-0.13 respectively). Carers having stronger 
beliefs in magical-religious causes of mental illness were associated with greater 
symptom severity in their family member (r=0.22, Caquero-Urizar et al., 2015). A 
systematic review of medication adherence among Asian Americans with mental illness 
found that the most successful interventions used psychoeducation that included both 
consumers and carers, and improved knowledge and attitudes among consumers and 
family caregivers coincided with clinical improvement (Fancher et al., 2014).  
Overall, research has demonstrated the potential impact carers have on consumer 
attitudes toward medication and the potential effects of consumer and carer beliefs on 
adherence outcomes. It is important to note that previous research has tended to cast 
carers and family members in an assisting or supervisory role, but did not consistently 
and clearly address the attitudinal nature by which this social support might influence 
consumer adherence behaviour. Moreover, it is not clear from previous research whether 
it is important that consumer and carer attitudes coincide for optimal adherence or 
whether discrepancies between attitudes are inconsequential. The current cross-sectional 
study is exploratory in nature and aims to investigate the relationships between carer and 
consumer attitudes toward medication and consumer adherence behaviour. Although 
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predominantly exploratory, given findings from prior research it was expected that 
consumer and carer attitudes towards medication and medication adherence would be 
positively correlated. The study aimed to explore whether consumer and carer attitudes or 
the discrepancy between these attitudes predicted self-reported medication adherence. 
2. Methods 
2.1 Procedure 
 Eligible consumers were individuals over the age of 18 with a serious mental 
illness requiring psychotropic medications and eligible carers were individuals over the 
age of 18 involved in the support of these consumers.  
All procedures were reviewed and approved by the relevant Human Research 
Ethics Committee (HE09/104). The sample was recruited with the support of the carer 
organisation Association of Relatives and Friends of the Mentally Ill (ARAFMI) in New 
South Wales (NSW), Australia. Two recruitment pathways were used. Firstly, a 
researcher attended carer support meetings run by ARAFMI NSW branches at Central 
Coast, Illawarra and Ryde and invited carers to participate. Secondly, staff at ARAFMI 
offered participation when carers rang the state head office to make an enquiry. If the 
carer provided informed consent, they were mailed or emailed a questionnaire pack with 
coordination of the carer organisation. The pack contained separate information sheets for 
consumers and carers, separate consumer and carer questionnaires, and reply paid 
envelopes. All questionnaires were matched with a code to maintain anonymity and 
returned directly to the researchers via the reply paid envelopes. This was an 
opportunistic convenience sample and given that staff at the ARAFMI services provided 
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information to potential participants we were unable to accurately determine the response 
rate. 
 
2.2 Measures  
2.2.1 Medication adherence 
The Brief Adherence Rating Scale (BARS; Byerly et al., 2008) consists of four 
items assessing different aspects of adherence: 
1. number of prescribed doses per day; 
2. how often a dose has been missed over the past month, rated from 1 (less than 7) to 
4 (more than 20); 
3. how often a consumer took less than prescribed dose over the past month, rated 
from 1 (76-100% of the time)  to 4 (0-25% of the time); and 
4. overall proportion (0-100%) of doses taken over the past month.  
The last item serves as the final adherence determination (Byerly et al., 2008). In a 
study with 61 consumers living with schizophrenia, the BARS showed excellent internal 
consistency (α=0.92) and good validity, sensitivity (73%), and specificity (71%; Byerly 
et al., 2008).   
The Kemp Clinician Rated Compliance Scale (CRCS; Kemp et al., 1996) comprises 
a single item rating scale in which respondents rate their level of compliance with 
medication on a seven-point Likert-type scale. The scale points are: 1 (complete refusal), 
2 (partial refusal), 3 (reluctant acceptance), 4 (occasional reluctance), 5 (passive 
acceptance), 6 (moderate participation), and 7 (active participation). The CRCS has 
been found to be a valid clinician-rated measure in medication adherence studies among 
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people with schizophrenia (Kemp et al., 1996; Tsang et al., 2009), and clinician and 
consumer rated CRCS have shown a medium correlation in a sample of people with 
schizophrenia (r=0.50; Friemann and Wciorka, 2013).The CRCS has shown a small 
correlation (r=0.25; Kikkert et al., 2008) with the self-reported Medication Adherence 
Questionnaire (Morisky et al., 1986). 
 
2.2.2 Attitudes towards medication 
The Drug Attitude Inventory – 10 (DAI-10; Hogan and Awad, 1992) measures 
satisfaction with medication and understanding of treatment effects. It consists of 10 
items that require either an agree/correct (scored 1) or disagree/incorrect (scored -1) 
response. The final score ranges from -10 to 10, with the higher the positive or lower the 
negative score reflecting extent of positivity or negativity towards medications.  Internal 
consistency using Cronbach’s alpha in the current study was 0.72 for consumers and 0.78 
for carers. 
The Beliefs About Medication Questionnaire (BMQ; Horne et al., 1999) – general 
beliefs subscale contains 8 items that assesses perceptions of the perceived potential for 
harm and overuse of medication. Items are rated using a 5-point Likert-type scale ranging 
from 1 (strongly agree) to 5 (strongly disagree). Higher scores represent more negative 
beliefs. The subscale has demonstrated acceptable internal consistency (>0.69) and 
validity among people with mental health disorders (Horne et al., 1999; Jonsdottir et al., 
2009). Cronbach’s alpha in the current study was 0.88 for consumers and 0.85 for carers.  
 
2.3 Analyses  
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Normality plots and statistical tests of normality were inspected. Results showed 
that the CRCS, BARS and DAI scores did not meet normality assumptions. Therefore we 
applied the nonparametric tests of Spearman’s correlations and bootstrapping for t-tests 
and regression analyses (5,000 samples).  
For all analyses we were interested in examining both consumer and carer 
reported adherence. This enabled judgments to be made about how results might be 
impacted by different respondent groups.  Also, a composite adherence measure was 
calculated using standardized scores on the CRCS and BARS4 (overall proportion of 
doses taken in prior month). The purpose was to maximize use of the adherence data and 
improve reliability from using single item scores only. The composite scores showed 
acceptable internal consistency for carers (α=0.76) and marginally acceptable internal 
consistency for consumers (α=0.66). 
Spearman’s correlations were used to test the associations between consumer and 
carer attitudes and adherence. Paired t-tests with bootstrapping were also used to detect 
any differences between carer and consumer scores on attitudinal and adherence 
measures. Attitude discrepancy was tested by calculating difference scores between 
consumer and carer attitude measures (BMQ and DAI). These difference scores were 
then correlated with consumer and carer rated adherence. 
Finally, the prediction of adherence was tested using regression analysis with 
bootstrapping. Separate multiple regressions with bootstrapping on the consumer and 
carer adherence composite scores were performed. In order to determine the variables to 
include in a regression analysis, correlations and t-tests were conducted between carer 
and consumer composite adherences scores with demographic and clinical characteristics 
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and both consumer and carer attitude measures. Given that use of difference scores as 
predictors in multiple regression usually leads to loss of model fit (Edwards, 2001), when 
a difference score and an individual score from which it was calculated (e.g. BMQ 
difference score and consumer BMQ score) both correlated significantly with the 
composite adherence score, we selected the individual scores for the regression.  
 
3. Results 
3.1 Sample characteristics  
The sample consisted of 42 carers and 42 of their family members with a mental 
illness who were receiving treatment (consumers). The mean age of carers was 54.61 
(SD=13.48, range=19-78) and the majority of carers were female (64%). Consumers 
(N=42) were equally distributed in gender and had a mean age of 41.21 (SD=14.63, 
range=18-67). Australia was the most frequently reported place of birth for participants 
with 79% of carers and 95% of consumers reported to be born in Australia. As shown in 
Table 1, the most frequent mental health diagnosis reported was 
schizophrenia/schizoaffective (43%), followed by bipolar (26%) and depression (17%). 
Carers were mostly parents (48%) and the most frequently reported period of care was 
over 10 years (57%).  
 
[INSERT Table 1] 
 
3.2 Descriptives 
Frequency analysis of the CRCS adherence scale for consumers revealed that 
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50% reported active participation, while 29% reported moderate participation. This is 
consistent with mean consumer BARS4 scores of 91.98% (SD=19.05) adherence to 
taking the recommended dosage in the past month.  For carers, half (50%) reported that 
consumers had active participation, 19% moderate participation, and 14% passive 
acceptance. This is also largely consistent with mean carer BARS4 scores of 92.26% 
(SD=19.07). 
 
3.3 Relationships between consumers and carers medication attitudes and 
adherence measures 
Consumer and carer reported adherence were strongly related for both the CRCS 
(r=0.67, p<0.01) and BARS4 (r=0.61, p<0.01) scores. Similarly, there was a strong 
positive correlation between carer and consumer scores on both the DAI-10 (r=0.72, 
p<0.01) and BMQ (r=0.66, p<0.01). Table 2 shows the results of paired t-tests with 
bootstrapping (5,000 samples) between consumer and carer adherence and attitude 
measures. The results indicated no significant differences between consumer and carer 
reported adherence on the CRCS or BARS4 (p<0.05) or attitudes on the DAI-10 and 
BMQ (p<0.05).  
 
[INSERT Table 2] 
 
3.4 Correlations between consumer and carer attitudes and consumer adherence  
Overall, there was a positive association between consumer and carer attitudes 
and adherence measures, such that the more positive the attitudes, the greater the 
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adherence (see Table 3). This pattern of relationships between attitude measures and 
adherence generally remains when comparing consumers and carers separately. Of note, 
specific attitudes seemed to relate more consistently with adherence than general attitudes 
(BMQ); carer general attitudes did not share a significant relationship with any adherence 
outcome. Also, the number of days in which less than the prescribed dose was taken 
(BARS3) was related to consumer attitudes only.  
 
[INSERT Table 3] 
 
3.5 Correlations between discrepancy in consumer and carer attitudes with 
consumer adherence 
Discrepancies in attitudes towards medication were correlated with both 
consumer and carer ratings of adherence (Table 3). The difference in specific attitudes 
(DAI-10 diff) was more consistently related to adherence than the difference in general 
attitudes (BMQ diff), which was related to carer reported CRCS ratings only. The greater 
the difference between consumer and carer specific attitudes, the lower the level of 
adherence.  
 
3.6 Consumer and carer attitudes predicting adherence  
Separate multiple regression analyses with bootstrapping (5,000 samples) were 
performed on consumer and carer composite adherence scores. Predictors entered for 
consumer reported adherence were consumer and carer DAI-10 scores. Predictors entered 
for carer reported adherence were consumer and carer DAI-10 scores and consumer 
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BMQ score. Correlations and t-tests showed that demographic and clinical characteristics 
were unrelated to the composite adherence scores (all p>0.05). 
Table 4 provides a summary of the regression results. For consumers, the model 
accounted for a significant 42% of the variance in consumer reported adherence 
F3,41=14.28, p<0.01. There were no significant unique predictors, although carer DAI-10 
approached significance (β=0.62, p=0.06). For carers, the model accounted for a 
significant 43% of the variance in carer reported adherence F3,41=9.56, p<0.01). 
Likewise, no predictors reached significance, although carer DAI-10 approached 
significance (β=0.60, p=0.06).  
 
[INSERT Table 4] 
 
4. Discussion 
As expected, consumer and carer adherence and attitudes towards medication were 
positively related. The magnitude of the correlation suggests shared attitudes toward 
medication. This research does not allow us to determine the extent or direction of 
influence between consumer and carer but the association of attitudes could be a result of 
a mutual influence process.   It is common for carers to simultaneously hold both positive 
and negative attitudes towards medication which could further influence the attitudes of a 
family member with mental illness.  For example, a European survey of carers of patients 
with schizophrenia showed that most carers recognized the importance of medication to 
help patients get better (76%) while at the same time believing it damages their general 
health (67%; Svettini et al., 2015). Such concerns are legitimate given the heightened 
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health risks associated with many antipsychotic medications (e.g., weight gain, new onset 
diabetes). The majority agreed on the importance of family support to boost adherence 
(93%), and acknowledged that treatment adherence was a burden for patients (65%), with 
a notable proportion indicating that it was a daily struggle to get patients to take their 
medication (38%). Although the current study provides preliminary evidence of the 
relationship between carer and consumer attitudes towards medications, there is a need 
for future longitudinal research in order to gain a better understanding of whether attitude 
transfer between carers and consumers is a bidirectional process. Clarifying the causal 
direction will help more effectively target interventions designed to improve medication 
adherence. 
Consumer and carer attitudes toward medication were associated with adherence, 
with more positive attitudes being associated with greater adherence. Specific attitudes 
(DAI-10) seemed more consistently related with adherence than general attitudes (BMQ). 
This was particularly for carers where their general attitudes did not relate at all to 
consumer or carer reported adherence. These initial findings suggest that, specific 
attitudes regarding how medication affects the consumer personally appear more useful 
in understanding adherence than more broad or general attitudes. Also, consumer reports 
of taking less than the prescribed dose (BARS3) were impacted by their own attitudes 
only.  
Partial support was found for the discrepancy in consumer and carer attitude towards 
medication correlating with adherence. In general, the findings indicated that the greater 
the difference between consumer and carer attitudes, the lower the level of adherence. 
The difference in DAI-10 scores was found to more consistently relate to adherence 
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outcomes on the CRCS and adherence composite, while the difference in BMQ scores 
related to carer reported CRCS adherence only. These results point to the importance of 
including consumers and carers as collaborators in clinical decision making regarding 
medication. The need to include carers in decisions about medication has been 
highlighted in a qualitative study of 29 carers in Australia with most indicating that they 
had been provided with little or no information about antipsychotic medication from 
treatment teams (Stomski & Morrison, 2017). Most carers expressed a desire to be 
involved in medication decision making but typically felt excluded from this process. The 
authors concluded that “health professionals need to substantially improve the extent to 
which they collaborate with carers in medication decisions” (Stomski& Morrison, 2017, 
p. 7). Toward this end, it may be helpful for treating clinicians to understand and address 
consumers and carers attitudes and concerns about medication given the relationship 
between discrepancy in views and adherence.  
 The regression models found that consumer and carer attitudes accounted for a 
substantial and significant amount of variance in adherence, but there were no unique 
predictors, although carer specific attitudes (DAI-10) approached significance and made 
a relatively strong contribution to the overall model.  It is notable that carer specific 
attitudes appear to have a substantial role in predicting adherence even when consumers’ 
specific and general attitudes are controlled. This result speaks to the importance of carer 
influence in consumer medication adherence and thus the need to target both carers and 
consumers with psychoeducational activities to increase adherence.  
A number of limitations to this study should be mentioned. This research is specific 
to an Australian sample, which impacts the generalisability of the results, while the 
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relatively small sample size impacts the generalisability of the results. Given the 
recruitment strategy relied on staff working within the carer support agency an accurate 
response rate was not able to be determined and leaving the possibility that unknown bias 
in the sample may have been introduced. In addition, because the sample was recruited 
through carer support agencies there may be unknown selection effects (e.g., carers with 
more knowledge of medications).  It is also possible that requiring consent from both 
carer and consumers may result in selection biases (e.g., more cooperative relationships). 
Since this was a cross-sectional survey causal links between attitudes and medication 
adherence cannot be determined. A longitudinal design in this research area would be 
valuable in exploring the dynamic interplay between consumer and carer attitudes and 
medication adherence. Finally, adherence was self-reported which is subject to a variety 
of response biases, namely social desirability in the current study. Future research in this 
area would benefit from incorporating other methodologies to determine medication 
adherence for corroboration of self-report data, such as electronic monitoring systems. 
Nonetheless, a strength of this study was the inclusion of multiple attitude and medication 
adherence measures. In addition, the novel dyad focus on consumer and their carers 
provided valuable information on the potential mutual influence processes effecting 
consumer medication adherence.  
 
4.1 Conclusions 
 This preliminary study suggests a strong link between consumer and carer 
attitudes toward medication and a positive association between both consumer and carer 
attitudes with consumer adherence. Moreover, regression analyses showed that while 
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neither consumer nor carer attitudes were significant unique predictors of adherence, 
carer attitudes may play as strong or stronger role in adherence than consumers’ attitudes. 
In addition, there was a general indication that the greater the difference between 
consumer and carer attitudes, the lower the level of adherence. These initial findings need 
to be extended in larger more representative samples, but they offer tantalizing 
possibilities should they be replicated in future research. Specifically, they offer 
opportunities for the development of interventions that target carer and consumer 
attitudes toward medication, with the potential of improving consumer medication 
adherence.  
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Table 1. Demographics and clinical characteristics of consumers (N=42) and carers 
(N=42). 
  
 Frequency Percent 
Mental health diagnosis   
Schizophrenia/ Schizoaffective 18 43 
Bipolar 11 26 
Depression 7 17 
Other 6 14 
Medication type   
Antipsychotic 29 69 
Antidepressant 7 17 
Not stated 4 10 
Other 2 5 
Treatment length   
0-2 years 1 2 
3-5 years 13 29 
6-9 years 8 18 
10 years and over 23 51 
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Note. Percentages do not always add to 100 due to rounding. 
 
 
  
Years as carer   
0-2 years 2 5 
3-5 years 8 19 
6-9 years 8 19 
10 years and over 24 57 
Carer relationship with consumer   
Parent 20 48 
Partner 15 36 
Child 6 14 
Friend 1 2 
 24
Table 2. Comparison of mean attitude and adherence scores for consumers and carers. 
 Consumer M(SD) Carer M(SD) t-value Boot 95 CI 
DAI-10 3.51 (5.08) 4.13 (4.98) 0.41 -0.71, 1.29 
BMQ 2.81 (.91) 2.59 (.82) -1.57 -0.41, 0.04 
CRCS 6.02 (1.56) 5.74 (1.65) -1.57 -0.55, 0.05 
BARS4 88.84 (24.12) 91.22 (19.57) 0.23 -2.12, 2.69 
Adherence 
composite 
-0.02 (.89) -0.02 (.93) -0.58 -0.16, 0.07 
Note 1. DAI-10=Drug Attitude Inventory – 10; BMQ=Beliefs About Medication 
Questionnaire; CRCS=Clinician Rated Compliance Scale; BARS4= Brief Adherence 
Rating Scale item 4 about the proportion of doses taken. 
Note 2. Boot 95 CI = bootstrap 95% confidence intervals. 
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Table 3. Correlations between consumer and carer attitude and adherence measures. 
 Consumer Carer 
Consumer CRCS BARS2 BARS3 BARS4 
Adherence 
composite CRCS BARS2 BARS3 BARS4 
Adherence 
composite 
DAI-10 0.28 -0.34* 0.31* 0.36* 0.34* 0.44** -0.44** 0.22 0.34* 0.47** 
BMQ -0.29 0.42* -0.32* -0.14 -0.26 -0.51** 0.49** -0.20 -0.13 -0.45** 
Carer           
DAI-10 0.46** -0.39** 0.22 0.37* 0.49** 0.62** -0.50** 0.18 0.25 0.59** 
BMQ -0.15 0.20 -0.12 -0.17 -0.18 -0.25 0.30 -0.02 -0.09 -0.24 
Difference 
scores 
          
DAI-10 diff 0.45** -0.27 0.04 0.08 0.35* 0.43* -0.20 0.02 -0.09 0.32* 
BMQ diff 0.16 -0.19 0.23 0.08 0.09 0.32* -0.23 0.19 0.09 0.23 
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* p<0.05, ** p<0.01 
Note. CRCS=Clinician Rated Compliance Scale; BARS2= Brief Adherence Rating Scale item 2 about number of days did not take 
medication; BARS3= Brief Adherence Rating Scale item 3 about number of days took less than prescribed number; BARS4= Brief 
Adherence Rating Scale item 4 about the proportion of doses taken; DAI-10 diff=difference score between consumer and carer Drug 
Attitude Inventory – 10 (DAI-10) ratings; BMQ diff= difference score between consumer and carer Beliefs About Medication 
Questionnaire (BMQ) ratings. 
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Table 4. Regression on consumer and carer standardized adherence scores. 
 
b Boot SE 
Boot 
95% CI 
% unique 
variance 
Consumer adherence 
scores 
    
Consumer DAI-10 0.01 0.03 -0.07, 0.06 0.09 
Carer DAI-10 0.10 0.04 0.02, 0.19 16.24 
Carer adherence scores     
Consumer DAI-10 -0.01 0.03 -0.09, 0.04 0.07 
Consumer BMQ -0.13 0.16 -0.45, 0.17 0.64 
Carer DAI-10 0.11 0.04 0.03, 0.20 14.75 
* p<0.05, ** p<0.01 
Note 1. DAI-10=Drug Attitude Inventory – 10; BMQ=Beliefs About Medication 
Questionnaire. 
Note 2. b = unstandardised regression coefficient; Boot SE = bootstrap standard error; 
Boot 95 CI = bootstrap 95% confidence intervals; % unique variance = percentage of 
unique variance accounted for in the adherence score, as indicated by the squared 
semipartial correlation coefficient. 
 
 
 
